Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

ACELRX PHARMACEUTICALS, INC.

UEI: RS3UJNCL6YG1

ACELRX PHARMACEUTICALS, INC. is a federal contractor, registered under UEI RS3UJNCL6YG1. It has been awarded $23,546,582 in federal contracts. Primary work spans Pharmaceutical Preparation Manufacturing and Unknown NAICS. Top awarding agencies include Department Of Defense.

Contact Information

Registration and classification details

Registration

UEI Code

RS3UJNCL6YG1

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

5

All time

Active

0

Currently performing

Completed

5

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ACELRX PHARMACEUTICALS, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ACELRX PHARMACEUTICALS, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ACELRX PHARMACEUTICALS, INC.'s top NAICS codes and agencies

NAICS: 541330
New
Federal
Army Contracting Command – Red River Army Depot (ACC-RRAD) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911RQ-27-S-C001
The Army Contracting Command – Red River Army Depot (ACC-RRAD) has issued solicitation W911RQ-27-S-C001, a Commercial Solutions Opening (CSO) aimed at modernizing the Organic Industrial Base (OIB). This initiative focuses on Convergent Manufacturing, integrating technologies such as digital twins, automation, cyber security, and connected digital enterprises to enhance the Defense Manufacturing Base. The CSO utilizes a streamlined acquisition process authorized by DFARS Subpart 212-70 and FAR Part 12, allowing the government to competitively procure innovative commercial items, technologies, and services from both traditional and non-traditional defense contractors. The overall solicitation remains open until September 30, 2027, with a general period of performance for individual awards typically not exceeding 12 months. The procurement is executed through specific Areas of Interest (AoIs), which have included diverse requirements such as the procurement of micro trucks, the replacement of fire suppression systems in Building 431, the installation of office cubicles, and the lease and maintenance of industrial parts washers. Evaluation occurs in three phases: an initial solution brief, a presentation or pitch, and a final Commercial Solutions Proposal (CSP). Technical proposals are evaluated on responsiveness, merit, and innovation, while price proposals must be determined as fair and reasonable. Awardees must be registered in the System for Award Management (SAM) and possess a Unique Entity ID (UEI). Specific projects may require additional certifications, such as Texas fire protection engineering licenses or environmental impairment liability insurance of up to 10 million dollars aggregate.
Department Of Defense

POSTED

1 day ago

DEADLINE

in 11 months
View Details
NAICS: 325412
New
Federal
6505--Nitroglycerin Patches
Solicitation # 36E79727R0010
The Department of Veterans Affairs National Acquisition Center is initiating an unrestricted procurement for Nitroglycerin Patches under solicitation 36E79727R0010. This contract will serve the VA, including Consolidated Mail Order Pharmacies and Option 2 State Veterans Homes, as well as the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The award will be granted to a single responsible offeror capable of providing an uninterrupted source of supply for a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs. The procurement covers four strengths of Nitroglycerin patches (0.1 mg, 0.2 mg, 0.4 mg, and 0.6 mg), with estimated annual usage ranging from 2,213 to 10,044 boxes. All patches must be supplied in boxes of 30 and must feature barcoding on both the individual patch and the outside box. Strict labeling requirements apply: the contractor must provide a unique NDC number, and their label must be the only one on the product, without being affixed over another label. Additionally, the labels must allow VA labels to adhere securely over them. This solicitation will be issued in commercial item format per FAR Part 12, with a tentative issuance date of December 1, 2026, and a closing date of December 15, 2026.
Nac Pharmaceuticals (36E797)

POSTED

1 day ago

DEADLINE

in 7 days
View Details
NAICS: 325412
New
International
Calcium Trisodium Pentetate (Ca-DTPA) ampoules
Solicitation # W6369-27-A062
The Department of National Defence, through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, is seeking the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel exposed to radioactive transuranic elements such as plutonium, americium, and curium. The required product must be a sterile solution for intravenous injection containing 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule, with a minimum shelf-life of 36 months from the date of manufacture. To ensure consistency with existing stockpiles for rapid emergency administration, the product must adhere to specific packaging and labelling standards and hold valid marketing authorization from Health Canada, the FDA, the EMA, or an EU member state. This procurement is being conducted via an Advance Contract Award Notice with an estimated total value of 47,500 CAD, including taxes and optional quantities. The contract is anticipated to run from the award date until March 31, 2031, featuring a firm requirement for 750 ampoules delivered in three annual increments of 250 starting no later than March 1, 2027. Additionally, the government has included an option for up to 500 more ampoules exercisable throughout the contract period. While Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG has been identified as the only known supplier capable of meeting these technical and regulatory requirements, other qualified suppliers may submit a Statement of Capabilities by November 25, 2026.
Department of National Defence

POSTED

1 day ago

DEADLINE

in 14 days
View Details